Last reviewed 2026-04-20 · How we verify

Eucatropin (EUCATROPINE)

Phase 2 active Small molecule

Eucatropin (generic name: EUCATROPINE) is a eucatropine drug. It is currently in Phase 2 development.

Eucatropine works by interacting with a specific target in the body to produce its therapeutic effects.

Eucatropine is a small molecule drug in the eucatropine class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or off-patent. The approved indications for eucatropine are also not specified. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety considerations. Further research is needed to understand the properties and uses of eucatropine.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EUCATROPINE
Drug class	eucatropine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, the exact way eucatropine works is not well understood, but it is thought to affect the nervous system in some way. More research is needed to determine the precise mechanism of action. It is possible that eucatropine may have effects on the parasympathetic nervous system, but this is purely speculative.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Eucatropin CI brief — competitive landscape report
Eucatropin updates RSS · CI watch RSS

Frequently asked questions about Eucatropin

What is Eucatropin?

Eucatropin (EUCATROPINE) is a eucatropine drug.

How does Eucatropin work?

Eucatropine works by interacting with a specific target in the body to produce its therapeutic effects.

What is the generic name of Eucatropin?

EUCATROPINE is the generic (nonproprietary) name of Eucatropin.

What drug class is Eucatropin in?

Eucatropin belongs to the eucatropine class. See all eucatropine drugs at /class/eucatropine.

What development phase is Eucatropin in?

Eucatropin is in Phase 2.

Drug class: All eucatropine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing